Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VTV THERAPEUTICS INC.

(VTVT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
1.25(c) 1.23(c) 1.14(c) 1.13(c) 1.15(c) Last
535 979 321 718 543 741 315 575 437 829 Volume
+0.81% -1.60% -7.32% -0.88% +1.77% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 4,50 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Sales 2022 1,00 M - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 77,0 M 77,0 M -
Capi. / Sales 2021 17,1x
Capi. / Sales 2022 77,0x
Nbr of Employees 25
Free-Float 33,6%
More Financials
Company
vTv Therapeutics Inc. is a clinical-stage pharmaceutical company that is engaged in the discovery and development of orally administered small molecule drug candidates. It is developing a program for the treatment of type I diabetes TTP399 and for psoriasis HPP737. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the... 
More about the company
All news about VTV THERAPEUTICS INC.
12/07VTV THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
12/06VTv Therapeutics Reduces Workforce By 65%; Shifts Focus to TTP399 Lead Program
MT
12/06VTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Opera..
AQ
12/02VTV THERAPEUTICS INC. : Change in Directors or Principal Officers, Financial Statements an..
AQ
12/02VTv Therapeutics Inc. Announces Resignation of Rudy Howard as Chief Financial Officer
CI
11/09VTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate ..
PU
11/09VTV THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
11/09VTV THERAPEUTICS : Q3 Earnings Snapshot
AQ
11/09VTv Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
CI
11/09Earnings Flash (VTVT) VTV THERAPEUTICS Posts Q3 Revenue $3M
MT
11/09VTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate ..
AQ
10/20VTV THERAPEUTICS : Names Deepa Prasad CEO, President
MT
10/20VTV THERAPEUTICS : Announces Deepa Prasad as New President and CEO - Form 8-K
PU
10/20VTV THERAPEUTICS INC. : Change in Directors or Principal Officers, Financial Statements an..
AQ
10/20VTV THERAPEUTICS : Announces Deepa Prasad as New President and CEO
PR
More news
News in other languages on VTV THERAPEUTICS INC.
12/06VTv Therapeutics réduit ses effectifs de 65 % et se concentre sur le programme principa..
11/09Earnings Flash (VTVT) VTV THERAPEUTICS affiche un chiffre d'affaires de 3 millions de d..
10/12L'essai du médicament contre le diabète de VTv Therapeutics atteint le critère principa..
09/24Les actions du secteur de la santé reculent vendredi
09/24VTv Therapeutics affirme que l'essai à doses croissantes démontre l'innocuité de son mé..
More news
Chart VTV THERAPEUTICS INC.
Duration : Period :
vTv Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VTV THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,15 $
Average target price 6,75 $
Spread / Average Target 487%
Managers and Directors
Deepa Prasad President, Chief Executive Officer & Director
Robin E. Abrams Executive Chairman
Aaron H. Burstein Senior Vice President-Clinical Development
Carmen Valcarce Chief Scientific Officer & Executive VP
Noel Joseph Spiegel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VTV THERAPEUTICS INC.-38.17%77
GILEAD SCIENCES, INC.19.29%87 180
BIONTECH SE310.30%67 585
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.75%63 017
VERTEX PHARMACEUTICALS-13.24%52 137